Lineage Cell Therapeutics Inc. (NYSEAMERICAN: LCTX) Gains After FDA Gives Feedback On OPC1 IND

June 29, 2021

Lineage Cell Therapeutics Inc. (NYSEAMERICAN: LCTX) gained 2.16% after releasing an update in OPC1’s clinical development. OPC1 is the company’s experimental allogeneic oligodendrocyte progenitor cell (OPC) transplant therapy for spinal cord injury treatment.  Lineage receives FDA feedback on OPC1 IND Last week the company received feedback from the FDA under the US FDA’s Regenerative Medicine Advanced Therapy program. As a result, Lineage is planning to submit an amendment to its…

Read More >>